Evaluation of endpoints in hypertension

Area of Science:

• Cardiology
• Hypertension Research
• Clinical Trials

Background:

• Cardiovascular mortality, including myocardial infarction and stroke, are primary endpoints in hypertension trials.
• Hard endpoints are often unrealistic in short-term trials with low-risk patients or in daily clinical practice.
• Intermediate or surrogate endpoints, such as blood pressure, are frequently used as substitutes.

Purpose of the Study:

• To evaluate the effectiveness of blood pressure control in reducing hard cardiovascular endpoints.
• To assess the relationship between achieved blood pressure levels and outcomes like stroke and myocardial infarction.
• To highlight the importance of blood pressure as a surrogate endpoint in hypertension management.

Main Methods:

• Utilizing data from large-scale intervention trials, such as the Hypertension Optimal Treatment (HOT) Study.
• Analyzing the correlation between treated blood pressure levels and hard endpoints (fatal/non-fatal stroke, myocardial infarction).
• Reviewing epidemiological studies demonstrating the link between blood pressure and cardiovascular prognosis.

Main Results:

• Blood pressure is a strong predictor of cardiovascular risk, especially stroke.
• The Hypertension Optimal Treatment (HOT) Study specifically investigates blood pressure levels against hard outcomes.
• Recent reports indicate that only a minority of treated hypertensive patients achieve adequate blood pressure control.

Conclusions:

• Blood pressure is a crucial and practical surrogate endpoint for cardiovascular risk in hypertension.
• Effective blood pressure management is essential for reducing cardiovascular mortality and morbidity.
• There is a significant unmet need in achieving optimal blood pressure control in the hypertensive population.